Abstract
In the last classification of cardiomyopathies (CM) presented by the European Society of Cardiology, CM are defined as myocardial disorders in which the heart muscle is structurally and functionally abnormal, in the absence of sufficient coronary artery disease, hypertension, valvular disease, and congenital heart disease to cause the observed myocardial abnormality. CM are then grouped into specific morphological and functional phenotypes, and each phenotype is subclassified into familial and nonfamilial forms (Fig. 2.1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2008;29(2):270-276.
Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10(10):933-989.
Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114(3):216-225.
Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841-842.
Maron BJ, McKenna WJ, Danielson GK, et al.; Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42(9):1687-1713.
Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807-1816.
Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004;363:1881-1891.
Morita H, Rehm HL, Menesses A, et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med. 2008;358(18):1899-1908.
Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 2001;104:557-567.
Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107:2227-2232.
Sanbe A, Nelson D, Gulick J, et al. In vivo analysis of an essential myosin light chain mutation linked to familial hypertrofic cardiomyopathy. Circ Res. 2000;87:296-302.
Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105(12):1407-1411.
DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med. 2003;348(26):2656-2668.
Blair E, Redwood C, Ashrafian H, et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet. 2001;10(11):1215-1220.
Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005;352:362-372.
Geier C, Perrot A, Özcerlik C, et al. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation. 2003;107:1390-1395.
Charron P, Villard E, Sébillon P, et al. Danon’s disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart. 2004;90(8):842-846.
Minamisawa S, Sato Y, Tatsuguchi Y, et al. Mutation of the phospholamban promoter associated with hypertrophic cardiomyopathy. Biochem Biophys Res Commun. 2003;304:1-4.
Raymen I, Holden HM, Sellers JR, et al. Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci USA. 1995;92:3864-3868.
Raymen I, Holden HM, Whittaker M, et al. Structure of the actin-myosin complex and its implications for muscle contraction. Science. 1993;261:58-65.
Schiaffino S, Reggiani C. Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Physiol Rev. 1996;76:371-396.
Marian AJ, Wu Y, Lim DS, et al. A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest. 1999;104:1683-1692.
Geisterfer-Lowrance AA, Christe M, Conner DA, et al. A mouse model of familial hypertrophic cardiomyopathy. Science. 1996;272:731-734.
Yang Q, Sanbe A, Osinska H, Hewett TE, Klevitsky R, Robbins J. A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. J Clin Invest. 1998;102(7):1292-1300.
Oberst L, Zhao G, Park JT, Brugada R, et al. Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. J Clin Invest. 1998;102(8):1498-1505.
Tardiff JC, Factor SM, Tompkins BD, et al. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J Clin invest. 1998;101:2800-2811.
Redwood CS, Moolman-Smook JC, Watkins H. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res. 1999;44(1):20-36.
Watkins H. Genetic clues to disease pathways in hypertrophic and dilated cardiomyopathies. Circulation. 2003;107(10):1344.
Gomes AV, Potter JD. Molecular and cellular aspects of troponin cardiomyopathies. Ann N Y Acad Sci. 2004;1015:214-224.
Knollmann BC, Kirchhof P, Sirenko SG, et al. Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling. Circ Res. 2003;92(4):428-436.
Olsson MC, Palmer BM, Stauffer BL, et al. Morphological and functional alterations in ventricular myocytes from male transgenic mice with hypertrophic cardiomyopathy. Circ Res. 2004;94:201-207.
Harris SP, Bartley CR, Hacker TA, et al. Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice. Circ Res. 2002;90:594-601.
Alpert NR, Mohiddin SA, Tripodi D, et al. Molecular and phenotypic effects of heterozygous, homozygous, and compound heterozygote myosin heavy-chain mutations. Am J Physiol Heart Circ Physiol. 2005;288(3):H1097-H1102.
Nagueh SF, Chen S, Patel R, et al. Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2004;36(5):663-673.
Doolan A, Tebo M, Ingles J, et al. Cardiac troponin I mutations in Australian families with hypertrophic cardiomyopathy: clinical, genetic and functional consequences. J Mol Cell Cardiol. 2005;38(2):387-393.
Schwartz K, Carrier L, Guicheney P, Komajda M. Molecular basis of familial cardiomyopathies. Circulation. 1995;91:532-540.
Gomes AV, Liang J, Potter JD. Mutations in human cardiac troponin I that are associated with restrictive cardiomyopathy affect basal ATPase activity and the calcium sensitivity of force development. J Biol Chem. 2005;280(35):30909-30915.
Gomes AV, Harada K. PotterJD. A mutation in the N-terminus of troponin I that is associated with hypertrophic cardiomyopathy affects tha Ca(2+)-sensitivity, phosphorilastion kinetics and proteolytic susceptibility of troponin. J Mol Cell Cardiol. 2005;39:754-765.
Gomes AV, Barnes JA, Harada K, Potter JD. Role of troponin T in disease. Mol Cell Biochem. 2004;263(1–2):115-129.
Gomes AV, Potter JD. Cellular and molecular aspects of familial hypertrophic cardiomyopathy caused by mutations in the cardiac troponin I gene. Mol Cell Biochem. 2004;263(1–2):99-114.
Redwood C, Lohmann K, Bing W, et al. Investigation of a truncated cardiac troponin T that causes familial hypertrophic cardiomyopathy: Ca(2+) regulatory properties of reconstituted thin filaments depend on the ratio of mutant to wild-type protein. Circ Res. 2000;86(11):1146-1152.
Crilley JG, Boehm EA, Blair E, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41(10):1776-1782.
Marian AJ, Roberts R. The molecular genetic basis for hypetrophic cardiomyopathy. J Mol Cell Cardiol. 2001;33:655-670.
Murphy RT, Mogensen J, McGarry K, et al. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J Am Coll Cardiol. 2005;45(6):922-930.
Ashrafian H, Redwood C, Blair E, et al. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet. 2003;19(5):263-268.
Kirschner SE, Becker E, Antognozzi M, et al. Hypertrophic cardiomyopathy-related β-myosin mutations cause highly varable calcium sensitivity with functional imbalances among individual muscle cells. Am J Physiol Heart Circ Physiol. 2005;288:H1242-H1251.
Pfeufer A, Osterziel KJ, Urata H, et al. Angiotensin-converting enzyme and heart chymase gene polymorphisms in hypertrophic cardiomyopathy. Am J Cardiol. 1996;78(3):362-364.
Yoneya K, Okamoto H, Machida M, et al. Angiotensin-converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Am Heart J. 1995;130(5):1089-1093.
Lechin M, Quiñones MA, Omran A, et al. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation. 1995;92(7):1808-1812.
Tesson F, Dufour C, Moolman JC. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. J Mol Cell Cardiol. 1997;29(2):831-838.
Richard P, Charron P, Leclercq C, et al. Homozygotes for a R869G mutation in the beta -myosin heavy chain gene have a severe form of familial hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2000;32(8):1575-1583.
Maron BJ, Spirito P, Green KJ, Wesley YE, Bonow RO, Arce J. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1987;10:733-742.
Chikamori T, Dickie S, Poloniecki JD, Myers MJ, Lavender JP, McKenna WJ. Prognostic significance of radionuclide-assessed diastolic dysfunction in hypertrophic cardiomyopathy. Am J Cardiol. 1990;65:478-482.
Bonow RO, Dilsizian V, Rosing DR, et al. Verapamil induced improvement in left ventricular filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy. Short and long-term effects. Circulation. 1985;72:853-864.
Pak PH, Maughan L, Baughman KL, Kass DA. Marked discordance between dynamic and passive diastolic pressure volume relations in idiopathic hypertrophic cardiomyopathy. Circulation. 1996;94(1):52-60.
Glancy DL, O’Brien KP, Gold HK, Epstein SE. Atrial fibrillation in patients with idiopathic hypertrophic subaortic stenosis. Br Heart J. 1970;32(5):652-659.
Fassbach M, Schwartzkopff B. Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Kardiol. 2005;94(5):328-335.
Lombardi R, Betocchi S, Losi MA, et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation. 2003;108(12):1455-1460.
Mundhenke M, Schwartzkopff B, Stark P, et al. Myocardial collagen type I and impaired left ventricular function under exercise in hypertrophic cardiomyopathy. Thorac Cardiovasc Surg. 2002;50(4):216-222.
Henry WL, Clarke CE, Epstein SE. Asymmetrical septal hypertrophy (ASH): Echocardiographic identification of the pathognomonic anatomic abnormality of IHSS. Circulation. 1973;42:225-233.
Shah PM, Gramiak R, Kramer DH. Ultrasound localization of left ventricular outflow obstruction in hypertrophic obstructive cardiomyopathy. Circulation. 1969;40(1):3-11.
Popp RL, Harrison DC. Ultrasound in the diagnosis and evaluation of therapy of idiopathic hypertrophic subaortic stenosis. Circulation. 1969;40(6):905-914.
Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol. 1981;48(3):418-428.
Mogensen J, Kubo T, Duque M, et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest. 2003;111(2):209-216.
Betocchi S, Bonow RO, Bacharach SL, et al. Isovolumic relaxation period in hypertrophic cardiomyopathy: assessment by radionuclide angiography. J Am Coll Cardiol. 1986;7(1):74-81.
Bonow RO, Frederick TM, Bacharach SL, et al. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. Am J Cardiol. 1983;51(8):1386-1391.
Betocchi S, Hess OM. LV hypertrophy and diastolic heart failure. Heart Fail Rev. 2000;5(4):333-336.
Ito T, Suwa M, Imai M, Nakamura T, Kitaura Y. Assessment of regional left ventricular filling dynamics using color kinesis in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2004;17(2):146-151.
McKenna WJ, Stewart JT, Nihoyannopoulos P, et al. Hypertrophic cardiomyopathy without hypertrophy: two families with myocardial disarray in the absence of increased myocardial mass. Br Heart J. 1990;63(5):287-290.
Waller BF, Maron BJ, Morrow AG, et al. Hypertrophic cardiomyopathy mimicking pericardial constriction or myocardial restriction. Am Heart J. 1981;102(4):790-792.
Thaman R, Gimeno JR, Murphy RT, et al. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart. 2005;91:920-925.
Thaman R, Gimeno JR, Reith S, et al. Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. J Am Coll Cardiol. 2004;44:398-405.
Sengupta PP, Mehta V, Arora R, et al. Quantification of regional nonuniformity and paradoxical intramural mechanics in hypertrophic cardiomyopathy by high frame rate ultrasound myocardial strain mapping. J Am Soc Echocardiogr. 2005;18(7):737-742.
Tabata T, Oki T, Yamada H, et al. Subendocardial motion in hypertrophic cardiomyopathy: assessment from long- and short-axis views by pulsed tissue Doppler imaging. J Am Soc Echocardiogr. 2000;13(2):108-115.
Yamada H, Oki T, Tabata T, et al. Assessment of left ventricular systolic wall motion velocity with pulsed tissue Doppler imaging: comparison with peak dP/dt of the left ventricular pressure curve. J Am Soc Echocardiogr. 1998;11(5):442-449.
Matsumura Y, Elliott PM, Virdee MS, et al. Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: relation to symptoms and exercise capacity. Heart. 2002;87(3):247-251.
Nagueh SF, Bachinski LL, Meyer D, et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation. 2001;104(2):128-130.
Losi MA, Betocchi S, Aversa M, et al. Dobutamine stress echocardiography in hypertrophic cardiomyopathy. Cardiology. 2003;100(2):93-100.
Okeie K, Shimizu M, Yoshio H, et al. Left ventricular systolic dysfunction during exercise and dobutamine stress in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2000;36(3):856-863.
Kawano S, Iida K, Fujieda K, et al. Response to isoproterenol as a prognostic indicator of evolution from hypertrophic cardiomyopathy to a phase resembling dilated cardiomyopathy. J Am Coll Cardiol. 1995;25(3):687-692.
Briguori C, Betocchi S, Manganelli F, et al. Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy. Eur Heart J. 2001;22(15):1328-1336.
Maron BJ, Tholakanahalli VN, Zenovich AG, et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation. 2004;109(8):984-989.
Noji Y, Shimizu M, Ino H, Higashikata T, et al. Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. Circ J. 2004;68(4):355-360.
Zen K, Irie H, Doue T, Takamiya M, et al. Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy. Int Heart J. 2005;46(2):231-244.
Högye M, Mándi Y, Csanády M, Sepp R, Buzás K. Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am J Cardiol. 2004;94(2):249-251.
Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102(8):858-864.
Ikeda H, Maki S, Yoshida N, et al. Predictors of death from congestive heart failure in hypertrophic cardiomyopathy. Am J Cardiol. 1999;83(8):1280-1283, A9.
Frank S, Braunwald E. Idiopathic hypertrophic subaortic stenosis. Clinical analysis of 126 patients with emphasis on the natural history. Circulation. 1968;37(5):759-788.
Goodwin JF, Hollman A, Cleland WP, Teare D. Obstructive cardiomyopathy simulating aortic stenosis. Br Heart J. 1960;22:403-414.
Wigle ED, Heimbecker RO, Gunton RW. Idiopathic ventricular septal hypertrophy causing muscular subaortic stenosis. Circulation. 1962;26:325-340.
Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis. 1985;28:1-83.
Maron BJ, Nishimura RA, Danielson GK. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. Circulation. 1998;98:2505-2508.
Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. Circulation. 1991;84:1188-1197.
Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: pathology and pathogenesis. Histopathology. 1995;26:493-500.
Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol. 1983;2:437-444.
Delling FN, Sanborn DY, Levine RA, et al. Frequency and mechanism of persistent systolic anterior motion and mitral regurgitation after septal ablation in obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2007;100(11):1691-1695.
He S, Hopmeyer J, Lefebvre XP, Schwammenthal E, Yoganathan AP, Levine RA. Importance of leaflet elongation in causing systolic anterior motion of the mitral valve. J Heart Valve Dis. 1997;6(2):149-159.
Levine RA, Vlahakes GJ, Lefebvre X, et al. Papillary muscle displacement causes systolic anterior motion of the mitral valve. Experimental validation and insights into the mechanism of subaortic obstruction. Circulation. 1995;91(4):1189-1195.
Maron BJ, Harding AM, Spirito P, et al. Systolic anterior motion of the posterior mitral leaflet: a previously unrecognized cause of dynamic subaortic obstruction in patients with hypertrophic cardiomyopathy. Circulation. 1983;68(2):282-293.
Spirito P, Maron BJ. Patterns of systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: assessment by two-dimensional echocardiography. Am J Cardiol. 1984;54(8):1039-1046.
Spirito P, Maron BJ. Significance of left ventricular outflow tract cross-sectional area in hypertrophic cardiomyopathy: a two-dimensional echocardiographic assessment. Circulation. 1983;67(5):1100-1108.
Reis RL, Bolton MR, King JF, et al. Anterion-superior displacement of papillary muscles producing obstruction and mitral regurgitation in idiopathic hypertrophic subaortic stenosis. Operative relief by posterior-superior realignment of papillary muscles following ventricular septal myectomy. Circulation. 1974;50(2 suppl):II181-II188.
Klues HG, Roberts WC, Maron BJ. Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. Circulation. 1993;87(5):1570-1579.
Klues HG, Proschan MA, Dollar AL, et al. Echocardiographic assessment of mitral valve size in obstructive hypertrophic cardiomyopathy. Anatomic validation from mitral valve specimen. Circulation. 1993;88(2):548-555.
Cannon RO, Dilsizian V, O’Gara PT, et al. Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation. 1991;83(5):1660-1667.
Pasternac A, Noble J, Streulens Y, et al. Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries. Circulation. 1982;65(4):778-789.
Camici P, Chiriatti G, Lorenzoni R, et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol. 1991;17(4):879-886.
Elliott PM, Rosano GM, Gill JS, et al. Changes in coronary sinus pH during dipyridamole stress in patients with hypertrophic cardiomyopathy. Heart. 1996;75(2):179-183.
Cannon RO III, Rosing DR, Maron BJ, et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation. 1985;71(2):234-243.
Morioka N, Shigematsu Y, Hamada M, Higaki J. Circulating levels of heart-type fatty acid-binding protein and its relation to thallium-201 perfusion defects in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2005;95(11):1334-1337.
Elliott PM, Kaski JC, Prasad K, et al. Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. Eur Heart J. 1996;17(7):1056-1064.
Cecchi F, Olivotto I, Gistri R, et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003;349(11):1027-1035.
Shimizu M, Ino H, Okeie K, et al. Exercise-induced ST-segment depression and systolic dysfunction in patients with nonobstructive hypertrophic cardiomyopathy. Am Heart J. 2000;140(1):52-60.
Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;22(3):796-804.
Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348(17):1647-1655.
Nugent AW, Daubeney PE, Chondros P, et al; National Australian Childhood Cardiomyopathy Study. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003;348(17):1639-1646.
Maron BJ. Hypertrophic cardiomyopathy in childhood. Pediatr Clin North Am. 2004;51(5):1305-1346.
Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med. 1986;315(10):610-614.
Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med. 1985;312(5):277-283.
Chikamori T, Doi YL, Yonezawa Y, Dickie S, Ozawa T, McKenna WJ. Comparison of clinical features in patients greater than or equal to 60 years of age to those less than or equal to 40 years of age with hypertrophic cardiomyopathy. Am J Cardiol. 1990;66(10):875-878.
Maron BJ, Schiffers A, Klues HG. Comparison of phenotypic expression of hypertrophic cardiomyopathy in patients from the United States and Germany. Am J Cardiol. 1999;83(4):626-627, A10.
Fay WP, Taliercio CP, Ilstrup DM, et al. Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coll Cardiol. 1990;16(4):821-826.
Gilligan DM, Chan WL, Ang EL, Oakley CM. Effects of a meal on hemodynamic function at rest and during exercise in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1991;18:429-436.
Lewis JF, Maron BJ. Clinical and morphologic expression of hypertrophic cardiomyopathy in patients > or = 65 years of age. Am J Cardiol. 1994;73(15):1105-1111.
McKenna WJ, Franklin RCG, Nihoyannopoulos P, et al. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1988;11:147-153.
Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999;281(7):650-655.
Spirito P, Chiarella F, Carratino L, et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med. 1989;320(12):749-755.
Prasad K, Williams L, Campbell R, Elliott PM, McKenna WJ, Frenneaux M. Episodic syncope in hypertrophic cardiomyopathy: evidence for inappropriate vasodilation. Heart. 2008;94(10):1312-1317.
Paz R, Jortner R, Tunick PA, et al. The effect of the ingestion of ethanol on obstruction of the left ventricular outflow tract in hypertrophic cardiomyopathy. N Engl J Med. 1996;335:938-941.
Savage DD, Seides SF, Clark CE, et al. Electrocardiographic findings in patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Circulation. 1978;58:402-409.
Maron BJ, Wolfson JK, Ciro E, Spirito P. Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy. Am J Cardiol. 1983;51:189-194.
Lemery R, Kleinebenne A, Nihoyannopoulos P, Alfonso F, McKenna WJ. Q-waves in hypertrophic cardiomyopathy in relation to the distribution and severity of right and left ventricular hypertrophy. J Am Coll Cardiol. 1990;16:368-374.
Fananapazir L, Tracey CM, Leon MB, et al. Electrophysiological abnormalities in patients with hypertrophic cardiomyopathy: a consecutive analysis in 155 patients. Circulation. 1989;80:1259.
Yamaguchi H, Ishimura T, Nishiyama S, et al. Hypertrophic nonobstructive cardiomyopathy with giant negative T-waves (apical hypertrophy): ventriculographic and echocardiographic features in 30 patients. Am J Cardiol. 1979;44:401-412.
Krikler DM, Davies MJ, Rowland E, Goodwin JF, Evans RC, Shaw DB. Sudden death in hypertrophic cardiomyopathy: associated accessory atrioventricular pathways. Br Heart J. 1980;43:245-251.
Adabag AS, Casey SA, Kuskowski MA, et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(5):697-704.
McKenna WJ, England D, Doi Y, Deanfield JE, Oakley CM, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy. 1. Influence on prognosis. Br Heart J. 1981;46:168-172.
Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol. 1981;48:252-257.
Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki J, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol. 1990;15:1279-1285.
Alfonso F, Frenneaux MP, McKenna WJ. Clinical sustained uniform ventricular tachycardia in hypertrophic cardiomyopathy: association with left ventricular apical aneurysm. Br Heart J. 1989;61:178-181.
Losi MA, Betocchi S, Aversa M, et al. Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2004;94(7):895-900.
Topol EJ, Califf RM, Prystowsky EN, et al. Textbook of Cardiovascular Medicine. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2007 [chapter 29].
Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26:1699-1708.
Doi YL, McKenna WJ, Gehrke J, et al. M mode echocardiography in hypertrophic cardiomyopathy: diagnostic criteria and prediction of obstruction. Am J Cardiol. 1980;45(1):6-14.
Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778-1785.
Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and age in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1989;13(4):820-823.
Panza JA, Petrone RK, Fananapazir L, Maron BJ. Utility of continuous wave Doppler echocardiography in the non-invasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1991;19:91-99.
Nishimura RS, Appleton CP, Redfield MM, et al. Nonivasive Doppler echocardiographic evaluation of left ventricular filling pressures in patients with cardiomyopathies: a simultaneous Doppler echocardiographic and cardiac catheterization study. J Am Coll Cardiol. 1996;28:1226-1233.
Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol. 1987;60:123-139.
Sharma S, Elliott P, Whyte G, et al. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol. 2000;86:162-168.
Jones S, Elliott PM, Sharma S, McKenna WJ, Whipp BJ. Cardiopulmonary responses to exercise in patients with hypertrophic cardiomyopathy. Heart. 1998;80:60-67.
Sadoul N, Prasad K, Elliott PM, Banerjee S, Frenneaux MP, McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96:2987-2991.
Maki S, Ikeda H, Muro A, et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol. 1998;82:774-778.
Olivotto I, Maron BJ, Montereggi A, et al. Prognostic value of systemic blood pressure response during exercise in a community based population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:2044-2051.
Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ. Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation. 1991;84:686-696.
Ciampi Q, Betocchi S, Lombardi R, et al. Hemodynamicv determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40:278-284.
Moon JCC, McKenna WJ, McCrohon JA, et al. Towards clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561-1567.
Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;53:121-123.
Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43(12):2260-2264.
Amano Y, Takayama M, Takahama K, et al. Delayed hyper-enhancement of myocardium in hypertrophic cardiomyopathy with asymmetrical septal hypertrophy: comparison with global and regional cardiac MR imaging appearances. J Magn Reson Imaging. 2004;20(4):595-600.
Moon JC, Mogensen J, Elliott PM, et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart. 2005;91(8):1036-1040.
Teraoka K, Hirano M, Ookubo H, et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging. 2004;22(2):155-161.
Sipola P, Lauerma K, Jääskeläinen P, et al. Cine MR imaging of myocardial contractile impairment in patients with hypertrophic cardiomyopathy attributable to Asp175Asn mutation in the alpha-tropomyosin gene. Radiology. 2005;236(3):815-824.
Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775-785.
Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA. 2002;287:1308-1320.
Cohen LS, Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation. 1967;35(5):847-851.
Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation. 1995;92(7):1680-1692.
Gilligan DM, Chan WL, Joshi J, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;21(7):1672-1679.
Sherrid MV, Pearle G, Gunsburg DZ. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation. 1998;97(1):41-47.
Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol. 1999;34(6):1813-1822.
Kaltenbach M, Hopf R, Kober G, Bussmann WD, Keller M, Petersen Y. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J. 1979;42(1):35-42.
Rosing DR, Kent KM, Maron BJ, et al. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation. 1979;60(6):1208-1213.
Bonow RO, Rosing DR, Bacharach SL, et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation. 1981;64(4):787-796.
Spicer RL, Rocchini AP, Crowley DC, Rosenthal A. Chronic verapamil therapy in pediatric and young adult patients with hypertrophic cardiomyopathy. Am J Cardiol. 1984;53(11):1614-1619.
Udelson JE, Bonow RO, O’Gara PT, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation. 1989;79(5):1052-1060.
Gistri R, Cecchi F, Choudhury L, et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol. 1994;74(4):363-368.
Iwase M, Sotobata I, Takagi S, et al. Effects of diltiazem on left ventricular diastolic behavior in patients with hypertrophic cardiomyopathy: evaluation with exercise pulsed Doppler echocardiography. J Am Coll Cardiol. 1987;9(5):1099-1105.
Pollick C. Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med. 1982;307:997-999.
Pollick C, Kimball B, Henderson M, Wigle ED. Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration. Am J Cardiol. 1988;62:1248-1251.
Matsubara H, Nakatani S, Nagata S, et al. Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1995;26:768-775.
Sherrid MV, Barac I, McKenna WJ, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(8):1251-1258.
Schulte HD, Bircks WH, Loesse B, Godehardt EA, Schwartzkopff B. Prognosis of patients with hypetrophic cardiomyopathy after transaortic myectomy. Late results up to twenty five years. J Thorac Cardiovasc Surg. 1993;106:709-717.
Morrow AG, Reitz BA, Epstein SE, et al. Operative treatment in hypertrophic subaortic stenosis: techniques and the results of pre and post-operative assessments in 83 patients. Circulation. 1975;52:88-102.
Maron BJ, Epstein SE, Morrow AG. Symptomatic status and prognosis of patients after operation for hypertrophic cardiomyopathy: efficacy of ventricular septal myotomy/myectomy. Eur Heart J. 1983;4(suppl F):175-180.
Williams WG, Wigle ED, Rakowski H, Smallhorn J, LeBlanc J, Trusler GA. Results of surgery for hypertrophic obstructive cardiomyopathy. Circulation. 1987;76:V104-V108.
Schoendube FA, Klues HG, Reith S, Flachskampf FA, Hanrath P, Messmer BJ. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation. 1995;92:II122-II127.
Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH III. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol. 2000;36:852-855.
Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart. 2000;83:326-331.
Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation. 1998;98:2415-2421.
Gietzen FH, Leuner CJ, Raute-Kreinsen U, et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J. 1999;20:1342-1354.
Knight C, Kurbaan AS, Seggewiss H, et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation. 1997;95:2075-2081.
Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol. 1998;31:252-258.
Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after non-surgical septal reduction therapy for hypertrophic cardiomyopathy. Circulation. 2001;103:1492-1496.
Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001;38:1701-1706.
Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol. 2001;38:1994-2000.
Firoozi S, Elliott P, Sharma S, et al. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. Eur Heart J. 2002;23:1617.
Gietzen FH, Leuner CJ, Obergassel L, et al. Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients. Heart. 2004;90(6):638-644.
Fernandes VL, Nagueh SF, Wang W, et al. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy–the Baylor experience (1996–2002). Clin Cardiol. 2005;28(3):124-130.
Chang SM, Lakkis NM, Franklin J, et al. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation. 2004;109(7):824-827.
Ralph-Edwards A, Woo A, McCrindle BW, et al. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. J Thorac Cardiovasc Surg. 2005;129(2):351-358.
Talreja DR, Nishimura RA, Edwards WD, et al. Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol. 2004;44(12):2329-2332.
Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet. 1992;339:1318-1323.
Nishimura RA, Trusty JM, Hayes DL, et al. Dual chamber pacing for hypertrophic cardiomyopathy: a randomised double-blind crossover trial. J Am Coll Cardiol. 1997;29:435-441.
Kappenberger L, Linde C, Daubert C, et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur Heart J. 1997;18:1249-1256.
Gadler F, Linde C, Daubert C, et al. Significant improvement of quality of life following atrioventricular synchronous pacing in patients with hypertrophic obstructive cardiomyopathy. Data from 1 year of follow-up. PIC study group. Pacing in cardiomyopathy. Eur Heart J. 1999;20:1044-1050.
Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation. 1999;99:2927-2933.
Betocchi S, Elliott PM, Briguori C, et al. Dual chamber pacing in hypertrophic cardiomyopathy: long-term effects on diastolic function. Pacing Clin Electrophysiol. 2002;25:1433-1440.
Fananapazir L, Epstein ND, Curiel RV, et al. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation. 1994;90(6):2731-2742.
Megevand A, Ingles J, Richmond DR, et al. Long-term follow-up of patients with obstructive hypertrophic cardiomyopathy treated with dual-chamber pacing. Am J Cardiol. 2005;95(8):991-993.
Ruzyłło W, Chojnowska L, Demkow M, et al. Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. Eur Heart J. 2000;21(9):770-777.
Biagini E et al. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol. 2005;46:1543-1550.
Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000;35:36-44.
Chien KR. Genotype, phenotype: upstairs, downstairs in the family of cardiomyopathies. J Clin Invest. 2003;111:175-178.
Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365-373.
Maron BJ, Estes NAM III, Maron MS, Almquist AK, Link MS, Udelson JE. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation. 2003;107:2872-2875.
Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36:2212-2218.
Rogers DP, Marazia S, Chow AW, Lambiase PD, et al. Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end stage hypertrophic cardiomyopathy. Eur J Heart Fail. 2008;10(5):507-513.
Ashrafian H, Mason MJ, Mitchell AG. Regression of dilated-hypokinetic hypertrophic cardiomyopathy by biventricular cardiac pacing. Europace. 2007;9:50-54.
Shirani J, Maron BJ, Cannon RO III, Shahin S, Roberts WC. Clinicopathologic features of hypertrophic cardiomyopathy managed by cardiac transplantation. Am J Cardiol. 1993;72:434-440.
Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104:2517-2524.
Maron BJ, Olivotto I, Bellone P, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39:301-307.
Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol. 1995;26:1529-1536.
McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: an important cause of sudden death. Arch Dis Child. 1984;59:971-975.
Elliott PM, Gimeno Blanes JR, Mahon NG, McKenna WJ. Relation between the severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001;357:420-424.
Kofflard MJ, Ten Cate FJ, van der Lee C, et al. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol. 2003;41:987-993.
Stafford WJ, Trohman RG, Bilsker M, Zaman L, Catellanos A, Myerburg RJ. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;7:701-704.
Maron BJ, Robert WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation. 1982;65:1388-1394.
Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33:1596-1601.
Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol. 1989;13:1283-1288.
Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, Cecchi F. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;41:315-321.
Saumarez RC, Chojnowska L, Derksen R, et al. Sudden death in noncoronary heart disease is associated with delayed paced ventricular activation. Circulation. 2003;107:2595-2600.
Silka MJ, Kron J, Dunnigan A, et al. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society. Circulation. 1993;87(3):800-807.
Kron J, Oliver RP, Norsted S, Silka MJ. The automatic implantable cardioverter-defibrillator in young patients. J Am Coll Cardiol. 1990;16(4):896-902.
Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298(4):405-412.
Taylor MR, Carniel E, Mestroni L. Cardiomyopathy, familial dilated. Orphanet J Rare Dis. 2006;1:27.
Bowles NE, Bowles KR, Towbin JA. Viral genomic detection and outcome in myocarditis. Heart Fail Clin. 2005;1(3):407-417.
Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007;50(19):1914-1931.
Weber MA, Ashworth MT, Risdon RA, et al. Clinicopathological features of paediatric deaths due to myocarditis: an autopsy series. Arch Dis Child. 2008;93(7):594-598.
Burkett EL, Hershberger RE. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol. 2005;45:969-981.
Dec GM, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med. 1994;331:1564-1575.
Mestroni L, Rocco C, Gregori D, et al. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. J Am Coll Cardiol. 1999;34:181-190.
Politano L, Nigro V, Nigro G, et al. Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. JAMA. 1996;275:1335-1338.
Bione S, D’Adamo P, Maestrini E, et al. A novel X-linked gene, G4.5. is responsible for Barth syndrome. Nat Genet. 1996;12(4):385-389.
Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med. 1999;341:1715-1724.
Hershberger RE, Hanson E, Jakobs PM, et al. A novel lamin A/C mutation in a family with dilated cardiomyopathy, prominent conduction system disease, and need for permanent pacemaker implantation. Am Heart J. 2002;144:1081-1086.
Towbin JA, Bowles NE. The failing heart. Nature. 2002;415(6868):227-233.
Towbin JA. The role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol. 1998;10:131-139.
Bowles NE, Bowles KR, Towbin JA. The “Final Common Pathway” hypothesis and inherited cardiovascular disease: the role of cytoskeletal proteins in dilated cardiomyopathy. Herz. 2000;25:168-175.
Towbin JA, Bowles NE. Dilated cardiomyopathy: a tale of cytoskeletal proteins and beyond. J Cardiovasc Electrophysiol. 2006;17(8):919-926.
Cox GF, Kunkel LM. Dystrophies and heart disease. Curr Opin Cardiol. 1997;12:329-343.
Feng J, Yan J, Buzin CH, et al. Mutations in the dystrophin gene are associated with sporadic dilated cardiomyopathy. Mol Genet Metab. 2002;77(1–2):119-126.
Feng J, Yan JY, Buzin CH, et al. Comprehensive mutation scanning of the dystrophin gene in patients with nonsyndromic X-linked dilated cardiomyopathy. J Am Coll Cardiol. 2002;40(6):1120-1124.
Taylor MR, Slavov D, Ku L, et al. Prevalence of desmin mutations in dilated cardiomyopathy. Circulation. 2007;115(10):1244-1251.
Van Tintelen JP, Hofstra RM, Katerberg H, et al. High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics. Am Heart J. 2007;154(6):1130-1139.
Parks SB, Kushner JD, Nauman D, et al. Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. Am Heart J. 2008;156(1):161-169.
Tsubata S. et al.Mutations in the human d-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest. 2000;106:655-662.
Barresi R, Di Blasi C, Negri T, et al. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by beta sarcoglycan mutations. J Med Genet. 2000;37(2):102-107.
Olson TM, Illenberger S, Kishimoto NY, et al. Metavinculin mutations alter actin interaction in dilated cardiomyopathy. Circulation. 2002;105(4):431-437.
Kärkkäinen S, Peuhkurinen K. Genetics of dilated cardiomyopathy. Ann Med. 2007;39(2):91-107.
Kamisago M et al. Mutations in sarcomeric protein genes as a cause of dilated cardiomyopathy. N Engl J Med. 2000;343:1688-1696.
Chang AN, Potter JD. Sarcomeric protein mutations in dilated cardiomyopathy. Heart Fail Rev. 2005;10(3):225-235.
Chang AN, Parvatiyar MS, Potter JD. Troponin and cardiomyopathy. Biochem Biophys Res Commun. 2008;369(1):74-81.
Murphy RT, Mogensen J, Shaw A, et al. Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet. 2004;363(9406):371-372.
Olson TM, Kishimoto NY, Whitby FG, Michels VV. Mutations that alter the surface change of a-tropomyosin are associated with dilated cardiomyopathy. J Mol Cell Cardiol. 2001;33:723-732.
Pyle WG, Solaro RJ. At the crossroads of myocardial signaling: the role of Z-discs in intracellular signaling and cardiac function. Circ Res. 2004;94(3):296-305.
Vatta M, Mohapatra B, Jimenez S, et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non- compaction. J Am Coll Cardiol. 2003;42(11):2014-2027.
Mohapatra B, Jimenez S, Lin JH, et al. Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol Genet Metab. 2003;80(1–2):207-215.
Knöll R, Hoshijima M, Hoffman HM, et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell. 2002;111(7):943-955.
Duboscq-Bidot L, Xu P, Charron P, et al. Mutations in the Z-band protein myopalladin gene and idiopathic dilated cardiomyopathy. Cardiovasc Res. 2008;77(1):118-125.
Hayashi T, Arimura T, Itoh-Satoh M, et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J Am Coll Cardiol. 2004;44(11):2192-2201.
Schmitt JP, Kamisago M, Asahi M, et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science. 2003;299(5611):1410-1413.
Haghighi K, Kolokathis F, Pater L, et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest. 2003;111(6):869-876.
McNair WP, Ku L, Taylor MR, et al. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder and arrhythmia. Circulation. 2004;100:2163-2167.
Nguyen TP, Wang DW, Rhodes TH, et al. Divergent biophysical defects caused by mutant sodium channels in dilated cardiomyopathy with arrhythmia. Circ Res. 2008;102:364-371.
Olson TM, Michels VV, Ballew JD, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA. 2005;293(4):447-454.
Arimura T, Hayashi T, Kimura A. Molecular etiology of idiopathic cardiomyopathy. Acta Myol. 2007;26(3):153-158.
LeWinter MM. Functional consequences of sarcomeric protein abnormalities in failing myocardium. Heart Fail Rev. 2005;10(3):249-257.
Towbin JA. Inflammatory cardiomyopathy: there is a specific matrix destruction in the course of the disease. Ernst Schering Res Found Workshop. 2006;(55):219-250.
Ahmad F, Seidman JG, Seidman CE. The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet. 2005;6:185-216.
Robinson P, Griffiths PJ, Watkins H, et al. Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments. Circ Res. 2007;101(12):1266-1273.
Arber S, Hunter JJ, Ross J Jr, et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell. 1997;88(3):393-403.
Zolk O, Caroni P, Böhm M, et al. Decreased expression of the cardiac LIM domain protein MLP in chronic human heart failure. Circulation. 2000;101(23):2674-2677.
Zhou Q, Chu PH, Huang C, et al. Ablation of Cypher, a PDZ-LIM domain Z-line protein, causes a severe form of congenital myopathy. J Cell Biol. 2001;155(4):605-612.
Granzier HL, Labeit S. The giant protein titin: a major player in myocardial mechanics, signaling, and disease. Circ Res. 2004;94(3):284-295.
Knowlton KU. CVB infection and mechanisms of viral cardiomyopathy. Curr Top Microbiol Immunol. 2008;323:315-335.
Badorff C, Knowlton KU. Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside. Med Microbiol Immunol. 2004;193(2–3):121-126.
Vatta M, Stetson SJ, Perez-Verdia A, et al. Molecular remodeling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet. 2002;359(9310):936-941.
Vatta M, Stetson SJ, Jimenez S, et al. Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assistdevices. J Am Coll Cardiol. 2004;43(5):811-817.
Parnaik VK. Role of nuclear lamins in nuclear organization, cellular signaling, and inherited diseases. Int Rev Cell Mol Biol. 2008;266:157-206.
Brodsky G, Muntoni F, Miocic S, Sinagra G, Sewry C, Mestroni L. Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation. 2000;101:473-476.
Becane HM, Bonne G, Varnous S, et al. High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing Clin Electrophysiol. 2000;23:1661-1666.
Jakobs PM, Hanson E, Crispell KA, et al. Novel lamin A/C mutations in two families with dilated cardiomyopathy and conduction system disease. J Card Fail. 2001;7:249-256.
Arbustini E, Pilotto A, Repetto A, et al. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defectrelated disease. J Am Coll Cardiol. 2002;39:981-990.
Taylor MR, Fain PR, Sinagra G, et al. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol. 2003;41:771-780.
Sebillon P, Bouchier C, Bidot LD, et al. Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations. J Med Genet. 2003;40:560-567.
Berko BA, Swift M. X-linked dilated cardiomyopathy. N Engl J Med. 1987;316(19):1186-1191.
Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919-928.
Towbin JA, Hejtmancik JF, Brink P, et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation. 1993;87(6):1854-1865.
Ervasti JM, Sonnemann KJ. Biology of the striated muscle dystrophin-glycoprotein complex. Int Rev Cytol. 2008;265:191-225.
Kaprielian RR, Stevenson S, Rothery SM, et al. Distinct patterns of dystrophin organization in myocyte sarcolemma and transverse tubules of normal and diseased human myocardium. Circulation. 2000;101(22):2586-2594.
Ségalat L, Grisoni K, Archer J, et al. CAPON expression in skeletal muscle is regulated by position, repair, NOS activity, and dystrophy. Exp Cell Res. 2005;302(2):170-179.
Petrof BJ, Shrager JB, Stedman HH, et al. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA. 1993;90(8):3710-3714.
Deconinck N, Dan B. Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr Neurol. 2007;36(1):1-7.
Davies KE, Nowak KJ. Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol. 2006;7(10):762-773.
Barth PG, Valianpour F, Bowen VM, et al. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update. Am J Med Genet A. 2004;126A(4):349-354.
Houtkooper RH, Vaz FM. Cardiolipin, the heart of mitochondrial metabolism. Cell Mol Life Sci. 2008;65(16):2493-2506.
Izawa H, Murohara T, Nagata K, et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation. 2005;112:2940-2945.
Goldman L, Ausiello D, eds. Cecil Medicine. 23 ed. Philadelphia: Saunders Elsevier; 2007 [chapters 59-68].
Kathy A, Crispell MD, Wray A, et al. Clinical profiles of four large pedigrees with familial dilated cardiomyopathy: preliminary recommendations for clinical practice. J Am Coll Cardiol. 1999;34(3):837-847.
Kilic T, Vural A, Ural D, et al. Cardiac resynchronization therapy in a case of myotonic dystrophy (Steinert’s disease) and dilated cardiomyopathy. Pacing Clin Electrophysiol. 2007;30(7):916-920.
Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med. 2008;358(25):2688-2697.
Lainscak M, von Haehling S, Springer J, Anker SD. Biomarkers for chronic heart failure. Heart Fail Monit. 2007;5(3):77-82.
Price JF, Thomas AK, Grenier M, et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation. 2006;114(10):1063-1069.
Heidecker B, Kasper EK, Wittstein IS, et al. Transcriptomic biomarkers for individual risk assessment in new-onset heart failure. Circulation. 2008;118(3):238-246.
Hamdan A, Shapira Y, Bengal T, et al. Tissue Doppler imaging in patients with advanced heart failure: relation to functional class and prognosis. J Heart Lung Transplant. 2006;25(2):214-218.
McMahon CJ, Nagueh SF, Eapen RS, et al. Echocardiographic predictors of adverse clinical events in children with dilated cardiomyopathy: a prospective clinical study. Heart. 2004;90(8):908-915.
Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48(10):1977-1985.
Yokokawa M, Tada H, Koyama K, et al. The characteristics and distribution of the scar tissue predict ventricular tachycardia in patients with advanced heart failure. Pacing Clin Electrophysiol. 2009;32(3):314-322.
Shimizu I, Iguchi N, Watanabe H, et al. Delayed enhancement cardiovascular magnetic resonance as a novel technique to predict cardiac events in dilated cardiomyopathy patients. Int J Cardiol. 2009;[Epub ahead of print]
Yokokawa M, Tada H, Toyama T, et al. Magnetic resonance imaging is superior to cardiac scintigraphy to identify nonresponders to cardiac resynchronization therapy. Pacing Clin Electrophysiol. 2009;32(suppl 1):S57-S62.
Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325(5):303-310.
Taylor AL, Ziesche S, Yancy C, et al.; African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049-2057.
Loeb HS, Johnson G, Henrick A, et al. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(6 suppl):VI78-VI87.
Vinge LE, Raake PW, Koch WJ. Gene therapy in heart failure. Circ Res. 2008;102(12):1458-1470.
Yamada S, Nelson TJ, Crespo-Diaz RJ, et al. Stem Embryonic stem cell therapy of heart failure in genetic cardiomyopathy. Cells. 2008;26(10):2644-2653.
Townsend D, Yasuda S, Li S, et al. Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol Ther. 2008;16(5):832-835.
Crispell K, Wray A, Ni H, Nauman D, Hershberger R. Clinical profiles of four large pedigrees with familial dilated cardiomyopathy: preliminary recommendations for clinical practice. J Am Coll Cardiol. 1999;34:837-847.
Hanson E, Hershberger RE. Genetic counseling and screening issues in familial dilated cardiomyopathy. J Genet Counseling. 2001;10:397-415.
Baig MK, Goldman JH, Caforio AP, Coonar AS, Keeling PJ, McKenna WJ. Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J Am Coll Cardiol. 1998;31:195-201.
Hershberger RE, Ni H, Crispell KA. Familial dilated cardiomyopathy: echocardiographic diagnostic criteria for classification of family members as affected. J Cardiac Fail. 1999;51:203-212.
The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
Crispell KA, Hanson E, Coates K, Toy W, Hershberger R. Periodic rescreening is indicated for family members at risk of developing familial dilated cardiomyopathy. J Am Coll Cardiol. 2002;39:1503-1507.
Sen-Chowdhry S, Lowe MD, Sporton SC, McKenna WJ. Arrhythmogenic right ventricular cardiomyopathy: clinical presentation, diagnosis, and management. Am J Med. 2004;117:685-695.
Sen-Chowdhry S, Syrris P, McKenna WJ. Genetics of right ventricular cardiomyopathy. J Cardiovasc Electrophysiol. 2005;16(8):927-935.
McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Br Heart J. 1994;71:215-218.
Thiene G, Nava A, Corrado D, et al. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988;318:129-133.
Corrado D, Fontaine G, Marcus FI, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation. Circulation. 2000;101(11):E101-E106.
Hamid MS, Norman M, Quraishi A, et al. Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy reveals a need to broaden diagnostic criteria. J Am Coll Cardiol. 2002;40:1445-1450.
Nava A, Thiene G, Canciani B, et al. Familial occurrence of right ventricular dysplasia: a study involving nine families. J Am Coll Cardiol. 1988;12:1222-1228.
Merner ND, Hodgkinson KA, Haywood AF, et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet. 2008;82:809-821.
Coonar AS, Protonotarios N, Tsatsopoulou A, et al. Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21. Circulation. 1998;97:2049-2058.
McKoy G, Protonotarios N, Crosby A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet. 2000;355:2119-2124.
Protonotarios N, Tsatsopoulou A, Anastasakis A, et al. Genotype-phenotype assessment in autosomal recessive arrhythmogenic right ventricular cardiomyopathy (Naxos disease) caused by a deletion in plakoglobin. J Am Coll Cardiol. 2001;38:1477-1484.
Rao BH, Reddy IS, Chandra KS. Familial occurrence of a rare combination of dilated cardiomyopathy with palmoplantar keratoderma and curly hair. Indian Heart J. 1996;48:161-162.
Carvajal-Huerta L. Epidermolytic palmoplantar keratoderma with woolly hair and dilated cardiomyopathy. J Am Acad Dermatol. 1998;39:418-421.
Norgett EE, Hatsell SJ, Carvajal-Huerta L, et al. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol Genet. 2000;9:2761-2766.
Getsios S, Huen AC, Green KJ. Working out the strength and flexibility of desmosomes. Nat Rev Mol Cell Biol. 2004;5:271-281.
Smith EA, Fuchs E. Defining the interactions between intermediate filaments and desmosomes. J Cell Biol. 1998;141:1229-1241.
Alcalai R, Metzger S, Rosenheck S, Meiner V, Chajek-Shaul T. A recessive mutation in desmoplakin causes arrhythmogenic right ventricular dysplasia, skin disorder, and woolly hair. J Am Coll Cardiol. 2003;42:319-327.
Rampazzo A, Nava A, Malacrida S, et al. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet. 2002;71:1200-1206.
Bauce B, Basso C, Rampazzo A, et al. Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations. Eur Heart J. 2005;26:1666-1675.
Norman M, Simpson M, Mogensen J, et al. Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation. 2005;112:636-642.
Jonkman MF, Pasmooij AM, Pasmas SG, et al. Loss of desmoplakin tail causes lethal acantholytic epidermolysis bullosa. Am J Hum Genet. 2005;77:653-660.
Whittock NV, Wan H, Morley SM, et al. Compound heterozygosity for non-sense and mis-sense mutations in desmoplakin underlies skin fragility/woolly hair syndrome. J Invest Dermatol. 2002;118:232-238.
Gerull B, Heuser A, Wichter T, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet. 2004;36:1162-1164.
Schwarz MA, Owaribe K, Kartenbeck J, Franke WW. Desmosomes and hemidesmosomes: constitutive molecular components. Annu Rev Cell Biol. 1990;6:461-491.
Awad MM, Dalal D, Cho E, et al. DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy. Am J Hum Genet. 2006;79:136-142.
Pilichou K, Nava A, Basso C, et al. Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation. 2006;113:1171-1179.
Heuser A, Plovie ER, Ellinor PT, et al. Mutant desmocollin-2 causes arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet. 2006;79:1081-1088.
Syrris P, Ward A, Evans A, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am J Hum Genet. 2006;79:978-984.
Beffagna G, De Bortoli M, Nava A, et al. Missense mutations in desmocollin-2 N-terminus, associated with arrhythmogenic right ventricular cardiomyopathy, affect intracellular localization of desmocollin-2 in vitro. BMC Med Genet. 2007;8:65.
Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997;30:1512-1520.
Nemec J, Edwards BS, Osborn MJ, Edwards WD. Arrhythmogenic right ventricular dysplasia masquerading as dilated cardiomyopathy. Am J Cardiol. 1999;84:237-239, A9.
De Pasquale CG, Heddle WF. Left sided arrhythmogenic ventricular dysplasia in siblings. Heart. 2001;86:128-130.
Michalodimitrakis M, Papadomanolakis A, Stiakakis J, Kanaki K. Left side right ventricular cardiomyopathy. Med Sci Law. 2002;42:313-317.
Suzuki H, Sumiyoshi M, Kawai S, et al. Arrhythmogenic right ventricular cardiomyopathy with an initial manifestation of severe left ventricular impairment and normal contraction of the right ventricle. Jpn Circ J. 2000;64:209-213.
Buja G, Estes N III, Wichter T, Corrado D, Marcus F, Thiene G. Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Risk Stratification and Therapy. Prog Cardiovasc Dis. 2008;50(4):282-293.
Protonotarios N, Tsatsopoulou A. Naxos disease and Carvajal syndrome: Cardiocutaneous disorders that highlight the pathogenesis and broaden the spectrum of arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Pathol. 2004;13:185-194.
Kaplan SR, Gard JJ, Carvajal-Huerta L, Ruiz-Cabezas JC, Thiene G, Saffitz JE. Structural and molecular pathology of the heart in Carvajal syndrome. Cardiovasc Pathol. 2004;13:26-32.
Duran M, Avellan F, Carvajal L. Dilated cardiomyopathy in the ectodermal dysplasia. Electro-echocardiographic observations in palmoplantar keratoderma with woolly hair. Rev Esp Cardiol. 2000;53:1296-1300.
Kaplan SR, Gard JJ, Protonotarios N, et al. Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease). Heart Rhythm. 2004;1:3-11.
Lemery R, Brugada P, Bella PD, et al. Nonischemic ventricular tachycardia. Clinical course and long-term follow-up in patients without clinically overt heart disease. Circulation. 1989;79:990-999.
Buxton AE, Waxman HL, Marchlinski FE, et al. Right ventricular tachycardia: clinical and electrophysiologic characteristics. Circulation. 1983;68:917-927.
Wilber DJ, Baerman J, Olshansky B, et al. Adenosine-sensitive ventricular tachycardia: clinical characteristics and response to catheter ablation. Circulation. 1993;87:126-134.
Nava A, Bauce B, Basso C, et al. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2000;36:2226-2233.
Ott P, Marcus FI, Sobonya RE, et al. Cardiac sarcoidosis masquerading as right ventricular dysplasia. Pacing Clin Electrophysiol. 2003;26:1498-1503.
Shiraishi J, Tatsumi T, Shimoo K, et al. Cardiac sarcoidosis mimicking right ventricular dysplasia. Circ J. 2003;67:169-171.
Lemola K, Brunckhorst C, Helfenstein U, et al. Predictors of adverse outcome in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: long-term experience of a tertiary care center. Heart. 2005;91:1167-1172.
Fontaine G, Fontaliran F, Frank R, et al. Causes of sudden death in athletes. Arch Mal Coeur Vaiss. 1989;82:107-111.
Tabib A, Miras A, Taniere P, Loire R. Undetected cardiac lesions cause unexpected sudden cardiac death during occasional sport activity. A report of 80 cases. Eur Heart J. 1999;20:900-903.
Corrado D, Thiene G, Nava A, et al. Sudden death in young competitive athletes: clinicopathologic correlations in 22 cases. Am J Med. 1990;89:588-596.
Furlanello F, Bertoldi A, Dallago M, et al. Cardiac arrest and sudden death in competitive athletes with arrhythmogenic right ventricular dysplasia. Pacing Clin Electrophysiol. 1998;21(1 pt 2):331-335.
Heidbuchel H, Hoogsteen J, Fagard R, et al. High prevalence of right ventricular involvement in endurance athletes with ventricular arrhythmias. Role of an electrophysiologic study in risk stratification. Eur Heart J. 2003;24:1473-1480.
Biffi A, Pelliccia A, Verdile L, et al. Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained athletes. J Am Coll Cardiol. 2002;40:446-452.
Henriksen E, Kangro T, Jonason T, et al. An echocardiographic study of right ventricular adaptation to physical exercise in elite male orienteers. Clin Physiol. 1998;18:498-503.
Sciomer S, Vitarelli A, Penco M, et al. Anatomico-functional changes in the right ventricle of the athlete. Cardiologia. 1998;43:1215-1220.
F.I. Marcus; W.J. McKenna; D. Sherrill; et al. Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Proposed Modification of the Task Force Criteria. Circulation. 2010;121(13):1533-1541.
Peters S, Trummel M. Diagnosis of arrhythmogenic right ventricular dysplasia-cardiomyopathy: value of standard ECG revisited. Ann Noninvasive Electrocardiol. 2003;8:238-245.
Fontaine G, Fontaliran F, Hebert JL, et al. Arrhythmogenic right ventricular dysplasia. Annu Rev Med. 1999;50:17-35.
Jaoude SA, Leclercq JF, Coumel P. Progressive ECG changes in arrhythmogenic right ventricular disease. Evidence for an evolving disease. Eur Heart J. 1996;17:1717-1722.
Turrini P, Angelini A, Thiene G, et al. Late potentials and ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol. 1999;83:1214-1219.
Kinoshita O, Fontaine G, Rosas F, et al. Time and frequency-domain analyses of the signal-averaged ECG in patients with arrhythmogenic right ventricular dysplasia. Circulation. 1995;91:715-721.
Burke AP, Robinson S, Radentz S, et al. Sudden death in right ventricular dysplasia with minimal gross abnormalities. J Forensic Sci. 1999;44:438-443.
Marcus FI, Fontaine GH, Frank R, et al. Long-term follow-up in patients with arrhythmogenic right ventricular disease. Eur Heart J. 1989;10(suppl D):68-73.
Wichter T, Borggrefe M, Haverkamp W, et al. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation. 1992;86:29-37.
Leclercq JF, Potenza S, Maison-Blanche P, et al. Determinants of spontaneous occurrence of sustained monomorphic ventricular tachycardia in right ventricular dysplasia. J Am Coll Cardiol. 1996;28:720-724.
Peters S, Peters H, Thierfelder L. Risk stratification of sudden cardiac death and malignant ventricular arrhythmias in right ventricular dysplasia-cardiomyopathy. Int J Cardiol. 1999;71:243-250.
Turrini P, Corrado D, Basso C, et al. Dispersion of ventricular depolarisation-repolarisation: a non-invasive marker for risk stratification in arrhythmogenic right ventricular cardiomyopathy. Circulation. 2001;103:3075-3080.
Turrini P, Corrado D, Basso C, et al. Noninvasive risk stratification in arrhythmogenic right ventricular cardiomyopathy. Ann Noninvasive Electrocardiol. 2003;8:161-169.
Tavernier R, Gevaert S, De Sutter J, et al. Long term results of cardioverter-defibrillator implantation in patients with right ventricular dysplasia and malignant ventricular tachyarrhythmias. Heart. 2001;85:53-56.
Link MS, Wang PJ, Haugh CJ, et al. Arrhythmogenic right ventricular dysplasia: clinical results with implantable cardioverter defibrillators. J Interv Card Electrophysiol. 1997;1:41-48.
Wichter T, Paul M, Eckardt L, et al. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD? Herz. 2005;30:91-101.
Blomström-Lundqvist C, Sabel KG, Olsson SB. A long term follow up of 15 patients with arrhythmogenic right ventricular dysplasia. Br Heart J. 1987;58(5):477-488.
Pinamonti B, Sinagra G, Salvi A, et al. Left ventricular involvement in right ventricular dysplasia. Am Heart J. 1992;123(3):711-724.
Peters S, Peters H, Thierfelder L. Heart failure in arrhythmogenic right ventricular dysplasia-cardiomyopathy. Int J Cardiol. 1999;71(3):251-256.
Corrado D, Leoni L, Link MS, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2003;108(25):3084-3091.
Hulot JS, Jouven X, Empana JP, et al. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation. 2004;110:1879-1884.
Peters S. Age related dilatation of the right ventricle in arrhythmogenic right ventricular dysplasia-cardiomyopathy. Int J Cardiol. 1996;56(2):163-167.
Marcus F, Nava A, Thiene G, et al. Arrhythmogenic RV Cardiomyopathy/Dysplasia, Recent Advances. Italia: Springer; 2007.
Pinamonti B, Miani D, Sinagra G, et al. Familial right ventricular dysplasia with biventricular involvement and inflammatory infiltration. Heart Muscle Disease Study Group. Heart. 1996;76(1):66-69.
Tonet JL, Castro-Miranda R, Iwa T, et al. Frequency of supraventricular tachyarrhythmias in arrhythmogenic right ventricular dysplasia. Am J Cardiol. 1991;67(13):1153.
Wlodarska EK, Wozniak O, Konka M, et al. Thromboembolic complications in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Europace. 2006;8(8):596-600.
Antonini-Canterin F, Sandrini R, Pavan D, et al. Right ventricular thrombosis in arrhythmogenic cardiomyopathy. A case report. Ital Heart J. 2000;1:415-418.
Chachques JC, Argyriadis PG, Fontaine G, et al. Right ventricular cardiomyoplasty: 10-year follow-up. Ann Thorac Surg. 2003;75:1464-1468.
Takagaki M, Ishino K, Kawada M, et al. Total right ventricular exclusion improves left ventricular function in patients with end-stage congestive right ventricular failure. Circulation. 2003;9:108.
Motta P, Mossad E, Savage R. Right ventricular exclusion surgery for arrhythmogenic right ventricular dysplasia with cardiomyopathy. Anesth Analg. 2003;96(6):1598-1602.
Pawel BR, de Chadarevian JP, Wolk JH, et al. Sudden death in childhood due to right ventricular dysplasia: report of two cases. Pediatr Pathol. 1994;14:987-995.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer London
About this chapter
Cite this chapter
Calcagnino, M., McKenna, W.J. (2010). Inherited Myocardial Diseases. In: Henein, M. (eds) Heart Failure in Clinical Practice. Springer, London. https://doi.org/10.1007/978-1-84996-153-0_2
Download citation
DOI: https://doi.org/10.1007/978-1-84996-153-0_2
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-84996-152-3
Online ISBN: 978-1-84996-153-0
eBook Packages: MedicineMedicine (R0)